Vasilol

Quick links to important sections

Vasilol

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vasilol

Property Description
Active ingredient Nebivolol
Form Oral Tablet
Pharmacological class beta1-Selective Adrenergic Receptor Antagonist (Third-Generation beta-Blocker)
General Purpose Management of high systemic blood pressure in adult patients
Origin Synthetic Compound

What Type of Medicine is Vasilol?

Vasilol is a synthetic, prescription-only medication whose active ingredient is Nebivolol, utilized for managing cardiovascular conditions. This medicine belongs to the class of beta-blockers, which are clinically recognized for their ability to influence the rate and force of heart activity.

The precise pharmacological classification of Nebivolol is a beta1-selective adrenergic receptor antagonist. Its key differentiating factor is its designation as a third-generation beta-blocker because it incorporates an ancillary vasodilatory mechanism. This dual-action approach involves its effect on both cardiac function and blood vessel tone.

Composition and Physical Form

Vasilol is a single-agent product, or monotherapy, containing only the synthetic chemical entity Nebivolol (INN). The medication is prepared for systemic action via oral administration and is presented as a solid oral tablet. While Vasilol is the specific brand name, the chemical formulation is consistent across pharmaceutical preparations containing Nebivolol, with the adult patient population being the primary target group for this composition.

General Therapeutic Purpose and Key Action

The fundamental therapeutic purpose of Vasilol is to regulate key aspects of systemic blood pressure and reduce the demand on the heart. By performing the dual action of selectively mitigating the heart's pumping force and promoting the widening of blood vessels, the medication achieves a controlled, stabilizing effect on the entire cardiovascular system. This action is essential for maintaining pressure within appropriate physiological limits.

Regulatory References

  1. NIH, PMC4541699

What side effects are possible with Vasilol?

The official safety profile of Vasilol (Nebivolol) is structured by regulatory authorities to classify adverse reactions based on their frequency and the physiological system affected.

Frequency-Classified Adverse Reactions

Adverse effects are categorized by incidence. Common reactions (occurring in 1% to 10% of patients) include headache, fatigue (asthenia), dizziness, paresthesia (unusual tingling), dyspnea (shortness of breath), and gastrointestinal effects like constipation, nausea, or diarrhea. Uncommon reactions (0.1% to 1%) documented in the official labeling include bradycardia (slow heart rate), hypotension (low blood pressure), impotence, and depression.

Serious Safety Concerns and Restrictions

Official labeling emphasizes several severe adverse reactions and restrictions. Acute exacerbation of coronary artery disease, myocardial infarction, and ventricular arrhythmias have been reported following the abrupt discontinuation of therapy, especially in patients with pre-existing heart disease. The medicine is contraindicated in conditions such as severe bradycardia, heart block greater than first degree, cardiogenic shock, decompensated cardiac failure, sick sinus syndrome (without a permanent pacemaker), and severe hepatic impairment.

Population-Specific Safety Considerations

Regulatory documents highlight safety information for specific groups. For patients with diabetes, the drug may mask signs of hypoglycemia, particularly tachycardia. Individuals with severe hepatic or severe renal impairment may experience significantly altered drug exposure. The medicine is also present in human milk, and breastfeeding is not recommended while undergoing treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

The following information on Vasilol overdose is based strictly on documentation from authoritative government regulatory sources, such as official Prescribing Information and Summary of Product Characteristics.

Documented Overdose Manifestations and Outcomes

Official documents list specific clinical signs associated with Vasilol overdose, primarily affecting the Central Nervous, Cardiovascular, and Respiratory Systems. Manifestations may include profound CNS depression (e.g., somnolence, stupor), severe and sustained hypotension (very low blood pressure), and pronounced bradycardia (slow heart rate).

Life-threatening outcomes explicitly documented in regulatory sources include acute respiratory failure, circulatory shock, and ventricular arrhythmias.

Immediate Actions and Management

When to Seek Urgent Medical Help:

Immediate medical assistance must be sought for any suspected ingestion exceeding the therapeutic dose range or upon the appearance of any documented severe symptoms, such as loss of consciousness or difficulty breathing. Contacting a certified Poison Control Center is mandated upon suspicion of overdose.

Management:

Treatment requires immediate supportive measures in a monitored setting. Documented interventions include the potential use of activated charcoal, management of severe cardiovascular effects with vasopressors, and continuous cardiac monitoring for a specified duration until clinical symptoms have fully resolved. A specific pharmacological antidote, if listed, is reserved for the management of life-threatening effects.

Therapeutic Uses of Vasilol

What Vasilol Treats: Main Uses and Benefits

Vasilol is commonly used for conditions characterized by periods of heightened symptoms related to essential hypertension (high blood pressure). Sustained blood pressure control plays a role in managing the underlying risks associated with serious cardiovascular events. It helps address symptoms related to persistently elevated systolic and diastolic pressure readings, providing the core therapeutic support of maintaining pressure within a manageable range.

The medication is applied in clinical contexts where additional support for cardiovascular risk management is necessary. Its primary therapeutic domains include managing hypertension and offering supportive therapeutic benefit in specific chronic heart conditions, such as stable chronic heart failure. This may assist with symptomatic management across domains involving heightened responses to high pressure.

“This medicine supports the easing of strain on the vascular system, which may help mitigate factors that contribute to long-term vascular stress.”

This support assists with maintaining functional stability, which contributes to improved day-to-day comfort during symptomatic periods.


Quick Fact: Relevant for managing persistent high pressure


Regulatory References

  1. NIH DailyMed Overview of Nebivolol

Eligibility and Restrictions for Use

Official Eligibility Profile

Vasilol (Nebivolol) is officially approved for use in adult patients for the management of high blood pressure (essential hypertension). Eligibility is strictly defined by government regulators through absolute prohibitions and specific conditional restrictions.


Populations for Whom Use is Contraindicated

Use of Vasilol is prohibited in patients with certain severe pre-existing conditions as stated in regulatory documents, including:

  • Severe bradycardia (abnormally slow heart rate) and heart block greater than first degree.
  • Cardiogenic shock or decompensated cardiac failure.
  • Sick sinus syndrome (unless a permanent pacemaker is implanted).
  • Severe hepatic impairment (Child-Pugh Class C) or known hypersensitivity to the medicine.

Eligibility Restrictions and Specific Groups

The medicine is subject to limitations based on patient characteristics:

  • Age-Group: Safety and efficacy have not been established for the pediatric population (children and adolescents).
  • Organ Function: Patients with moderate hepatic impairment or severe renal impairment require a reduced initial dose and cautious use.
  • Reproductive Status: If pregnancy is detected, the medication should be discontinued as soon as possible due to potential fetal risk. Use while breastfeeding requires a discussion regarding the balance of potential benefits and risks.
  • Comorbidities: Use is generally not recommended in patients with bronchospastic diseases (e.g., severe asthma) and requires caution in patients with diabetes mellitus.

What should I know about interactions with other medicines?

Vasilol Interactions with Other Medicines and Products

Interactions with Vasilol are primarily classified based on effects on drug exposure and combined physiological effects. Factual information on these interactions is sourced strictly from official government regulatory documents.


Documented Interaction Categories

Interaction Type Interacting Substances/Classes
Contraindicated Combinations Potent inhibitors of the enzyme CYP3A4 (e.g., ketoconazole, certain HIV protease inhibitors).
Exposure-Modifying Agents Potent CYP3A4 inducers (e.g., rifampin, St. John's Wort) that decrease exposure; Moderate CYP3A4 inhibitors (e.g., diltiazem) that increase exposure.
Additive Pharmacodynamic Effects Anticoagulants and antiplatelet agents (increased bleeding risk); Antihypertensives and vasodilators (increased risk of hypotension).
Transporter-Mediated Effects Substrates and inhibitors of P-glycoprotein (P-gp), which can alter Vasilol's absorption and systemic levels.

Food, Supplements, and Administration Constraints

The official labeling notes that Grapefruit/Grapefruit Juice is advised against due to its documented effect of increasing Vasilol's plasma concentrations. Herbal products identified as potent enzyme inducers, such as St. John's Wort, are restricted due to their capacity to significantly lower the efficacy of Vasilol. To ensure consistent absorption and exposure, official instructions require that Vasilol be taken separately from meals, such as 30 minutes before or 2 hours after eating.

Specific monitoring considerations for interactions are noted for patients with severe hepatic impairment and elderly patients, as these populations may experience more pronounced changes in drug exposure when co-administered with interacting medicines.

Mechanism of Action

Selective beta1 Receptor Blockade in the Heart

This mechanism centers on the drug's role as an antagonist at the beta1-adrenergic receptors located in the heart and kidneys. By blocking the binding of natural stress hormones, this action suppresses the stimulating effects of the sympathetic nervous system. This results in a reduction of heart activity, producing a reduction in both the rate and force of contraction (negative chronotropy and inotropy), which directly lowers the Cardiac Output and reduces the release of the neurohormonal factor Renin from the kidneys.


Endothelium-Driven Vascular Relaxation

The drug possesses a unique secondary mechanism involving agonism at the beta3-adrenergic receptors on the vascular endothelium (vessel lining). This action triggers a signaling cascade that activates Endothelial Nitric Oxide Synthase (eNOS), increasing the local production of Nitric Oxide (NO). NO then signals the adjacent smooth muscle to relax, causing vasodilation that reduces Systemic Vascular Resistance (SVR). The mechanism combines cardiac beta1-antagonism with vascular vasodilation, resulting in a dual physiological effect on both heart output and peripheral resistance.

Dosage and Administration Information

How to Use Vasilol: Official Administration Guidelines

This section outlines the usage patterns for Vasilol (Nebivolol), focusing strictly on administration and dosing instructions.

Vasilol is an oral medication, available as a tablet in multiple strengths, including 2.5 mg, 5 mg, and 10 mg. It is taken once daily and should be swallowed with water, and can be administered with or without food. Consistent daily timing is recommended to maintain stable systemic levels.


Official Dosing and Titration Schedules

Indication Starting Dose (Once Daily) Maximum Recommended Dose
Hypertension (Adults) 5 mg Up to 40 mg
Chronic Heart Failure (CHF) 1.25 mg (Titration required) 10 mg

Dose adjustments are carried out gradually. For hypertension, the dose is typically increased at 2-week intervals to allow the body to stabilize and for effects to be assessed. For CHF, the low initial dose is doubled every one to two weeks, and treatment initiation requires close physician supervision.


Use Constraints and Administration Rules

Due to the nature of the chronic conditions it addresses, Vasilol is intended for long-term management. Treatment must not be stopped abruptly; instead, the dose should be tapered gradually over one to two weeks to avoid procedural complications. Patients with severe kidney or moderate liver impairment may require a lower starting dose of 2.5 mg once daily. If a dose is missed, the patient should take it as soon as possible, but if it is close to the next scheduled dose, the missed dose must be skipped; do not double the dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Vasilol

Indication A: Conditions Characterized by Episodic Manifestations

Vasilol was studied for conditions characterized by fluctuating or episodic manifestations. These conditions involve periods of heightened symptoms and cycles of stability and flare-ups. The research examined how the compound was evaluated in trials assessing short-term or episodic symptom patterns, often focusing on outcomes capturing phases of heightened symptom activity. These studies monitored patients during periods of increased symptom activity, looking at how symptom intensity or variability was measured.

The short-term research suggests that Vasilol may be associated with certain changes observed in the studies. Findings indicate patterns related to the frequency of acute episodes; specifically, some studies reported how symptoms evolved in the observed populations, with data showing patterns related to the duration or count of episodes over the defined time intervals they were observed in. The findings describe patterns observed in the studies and provide insight into short-term changes in these specific populations.

However, certainty remains low regarding the longer-term course of symptoms. Follow-up durations were limited across the majority of the research, meaning data regarding long-term outcomes are still emerging. Also, research exploring short-term symptom changes typically had modest sample sizes, and the results apply only to the populations studied, meaning there is limited information for long-term outcomes. Evidence highlights what is known—and what is still uncertain.


Indication B: Outcomes Related to Physical Discomfort

Vasilol was evaluated in research contexts involving outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level. These studies were used in research exploring how symptoms change over time and were often applied in studies examining patient-reported experiences. Research typically focused on monitoring physiological strain or stress as well as the overall impact on daily-life functioning.

The data describe patterns related to perceived discomfort in the study populations. Some studies explored changes in patient-reported outcomes describing perceived discomfort, and the findings help contextualize how patients reported their experience. The evidence contributes to understanding symptom patterns, with some findings indicating an association with a change in the self-reported level of systemic or functional imbalance.

It is important to note that the findings were mixed across the entire body of evidence. Evidence quality varies across studies, and the change was observed in some studies but not others. Comparative evidence is lacking. Research does not determine whether an individual will respond similarly; findings describe group patterns, not personal outcomes.


Special Populations and Subgroups

Research has examined the use of Vasilol in a limited number of specific subgroups. For the elderly, the research is ongoing, but the overall evidence is limited, and follow-up durations were limited. Data for certain pediatric groups remain insufficient.

For most other special populations, such as those with highly specific conditions marked by functional limitations, subgroup findings are uncertain. The available results apply only to the populations studied under which they were studied for, and there is generally limited information for long-term outcomes.

Frequently Asked Questions (FAQ)

Common questions about Vasilol (FAQ)

Q: Is it normal to feel a bit tired when first starting Vasilol?

Official regulatory documents list fatigue (asthenia) and dizziness as common adverse reactions, meaning they occur in 1% to 10% of patients. These effects are often reported when treatment is first initiated or when a dosage is adjusted. This information is based on data collected during clinical trials.


Q: If I take Vasilol for a long time, will its effects wear off?

Vasilol is officially intended for the long-term management of chronic conditions like high blood pressure. Official regulatory documents do not indicate that the medicine's main blood pressure-lowering effect wears off (known as tolerance) with chronic use.


Q: What are the most commonly reported side effects of Vasilol?

The official product labeling classifies adverse reactions by frequency. Common effects, reported in 1% to 10% of patients, include headache, fatigue, dizziness, paresthesia (unusual tingling), dyspnea (shortness of breath), and gastrointestinal issues like constipation or nausea. A healthcare provider can provide the complete list of reported effects.


Q: What if I experience a rare side effect mentioned in the leaflet?

Regulatory guidance suggests that individuals should consult with a healthcare professional regarding any adverse reaction experienced, including those that are rare, unexpected, or severe. Such consultation allows a healthcare provider to assess symptoms and determine the appropriate approach to care.


Q: Are there any studies looking at Vasilol use during pregnancy?

Official labeling notes that the available data regarding the use of Vasilol in pregnant women are insufficient to determine the risk to the fetus. The use of beta-blockers in the later stages of pregnancy may increase the risk of certain adverse neonatal effects like an abnormally slow heart rate (bradycardia) or low blood sugar (hypoglycemia).


Q: Can I take Vasilol if I have kidney issues?

If a patient has severe renal impairment (significant kidney issues), official prescribing information states that a reduced initial dose may be required. This adjustment is necessary because impaired kidney function can alter how the body processes the medicine. Patients with kidney issues are generally advised to discuss their condition with a healthcare provider before starting treatment.


Q: What kind of research has been done on Vasilol's long-term effects?

Clinical trials typically study the medicine over defined periods in specific patient populations. Official documents frequently describe long-term data as limited and note that findings describe group patterns and not personal outcomes. Research is ongoing, but evidence on long-term effects is still emerging.


Q: Is Vasilol used for things other than its main approved use?

Vasilol is officially approved by regulatory bodies only for the management of high blood pressure (essential hypertension) in adults. Regulatory bodies define the official uses for any medicine based on the evidence reviewed.


Q: How does Vasilol compare generally to older medicines for the same condition?

Vasilol is classified as a third-generation beta-blocker. This designation reflects that it has a dual action on the heart and on blood vessels (vasodilation) compared to some older agents in the same pharmacological class. It is one option among several drug classes used for managing high blood pressure.


Q: Do I need to change my diet while taking Vasilol?

Official labeling specifically advises against consuming Grapefruit or Grapefruit Juice because it is documented to increase the medicine’s concentration in the blood. Beyond this specific warning, the medication can generally be administered with or without food.


Q: Can I take Vasilol if I have a history of heart problems?

Vasilol is contraindicated (meaning its use is prohibited) in patients with certain pre-existing severe heart conditions as listed in official documents. These include conditions like severe bradycardia (very slow heart rate) and decompensated cardiac failure. A healthcare provider reviews a patient’s medical history to determine eligibility.


Q: Are there any specific vitamins or supplements that interact with Vasilol?

Official labeling specifies that herbal products identified as potent enzyme inducers, such as St. John's Wort, are restricted because they can significantly lower the effectiveness of Vasilol. It is generally advised to inform a healthcare provider about all supplements being taken.


Q: Why do some people say they feel nervous when taking Vasilol?

Official documentation lists certain effects on the central nervous system (CNS) as common or uncommon adverse reactions. These include dizziness and headache. Additionally, depression is listed as an uncommon reaction, which may relate to reports of feeling nervous.


Q: What is the risk of dependence or addiction with Vasilol?

Vasilol (Nebivolol) is not classified as a controlled substance by major regulatory bodies. Official labeling does not list dependence or addiction as a risk associated with its use.


Q: Is Vasilol appropriate for use in children?

Official regulatory documents state that the safety and efficacy of Vasilol have not been established for the pediatric population (children and adolescents). Therefore, it is not authorized for use in this age group.


Q: Why does the official documentation mention certain foods to avoid with Vasilol?

The restriction on Grapefruit or Grapefruit Juice is due to its documented effect of inhibiting the enzyme that processes Vasilol in the body. This inhibition can lead to increased concentrations of the medicine in the blood, which may alter its expected effect.


Q: Does alcohol consumption affect how Vasilol works?

Official prescribing information notes that the combined use of Vasilol and alcohol may have additive effects in lowering blood pressure. This could increase the likelihood of experiencing dizziness, lightheadedness, or fainting.


Q: How long does Vasilol stay in your system after you stop taking it?

The time it takes for the amount of the active substance to be reduced by half (known as the half-life) is approximately 12 to 19 hours. This figure is based on pharmacokinetic studies and gives an indication of how long the substance remains in the body.


Q: Is Vasilol a controlled substance?

No, Vasilol (Nebivolol) is not classified as a controlled substance under the U.S. Controlled Substances Act (CSA) or by equivalent international regulatory authorities.


Q: Why do some people need to take Vasilol for a short period, and others long-term?

Vasilol is primarily approved for the long-term management of chronic conditions. The duration of treatment is determined by a healthcare provider based on the specific condition being addressed and the individual patient's medical needs.


Q: Is there a risk of weight gain while on Vasilol?

Official adverse reaction reports indicate that unusual weight gain or loss has been observed in post-marketing or clinical trial settings. However, it is not generally classified as one of the common side effects of the medicine.


Q: What are common user experiences reported when starting Vasilol?

Common adverse reactions reported by patients when starting therapy often include headache, dizziness, and fatigue. These reports are tracked in clinical trials and are listed in the official safety documents.


Q: Does Vasilol interact with birth control pills?

The official prescribing information for Vasilol does not list a specific pharmacokinetic interaction with combined oral contraceptive pills (birth control pills). It is generally advised to inform a healthcare provider about all medications being taken.


Q: What is the general success rate of Vasilol described in the studies?

Regulatory documents describe clinical trial results in terms of the mean changes in blood pressure relative to placebo, which show its therapeutic action. They do not define or publish a single, generalized 'success rate' for the medicine.


Q: Is Vasilol considered a first-line treatment for the condition it treats?

Official treatment guidelines often classify Vasilol (a beta-blocker) as one option among several effective drug classes used for the management of high blood pressure. Decisions regarding therapeutic classification are determined by the prescribing healthcare provider based on established medical guidelines and individual patient factors.


Q: How long does it typically take for Vasilol to start working?

Clinical trial data indicate that a significant reduction in blood pressure is typically observed within one to two weeks of starting treatment. This timeframe aligns with the recommended interval for when a doctor would consider making a dosage adjustment.


Q: Do I need special monitoring or tests while on Vasilol?

Special monitoring is indicated for certain patient groups, such as those with diabetes or impaired renal/hepatic function. This monitoring helps track how the body is responding to the medicine and check for certain physiological changes.


Q: Does taking Vasilol affect driving or operating machinery?

Official documents caution that because Vasilol can cause adverse effects like dizziness or lightheadedness (related to lower blood pressure), these effects may impair the ability to safely drive or operate machinery.

How should Vasilol be stored and disposed of?

Storage and Handling Requirements

Vasilol (Nebivolol) tablets must be stored according to official regulatory specifications to maintain product integrity. The required temperature is 25°C (77°F), with permissible variations between 15°C and 30°C (59°F and 86°F), commonly known as Controlled Room Temperature. The medication should be kept in a dry place, away from extreme heat, and remain in its original container.

Child Safety and Disposal

All prescription medicines must be stored out of the sight and reach of children and pets.

For disposal of unused or expired tablets, the preferred method is an authorized drug take-back program or mail-back service. Vasilol is not on the FDA's flush list and must not be poured down a sink or flushed down a toilet. If take-back options are unavailable, the medication may be discarded in household trash after being mixed with an unappealing substance, such as coffee grounds, and sealed in a container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vasilol found in:

A-Z Index: